Presentation is loading. Please wait.

Presentation is loading. Please wait.

Glycemic thresholds for secretion of counterregulatory hormones and onset of physiological, symptomatic, and cognitive changes in response to hypoglycemia.

Published byIvan Ridwan Budiaman Modified over 6 years ago

Similar presentations

Presentation on theme: "Glycemic thresholds for secretion of counterregulatory hormones and onset of physiological, symptomatic, and cognitive changes in response to hypoglycemia."— Presentation transcript:

1 Glycemic thresholds for secretion of counterregulatory hormones and onset of physiological, symptomatic, and cognitive changes in response to hypoglycemia in the nondiabetic human. Glycemic thresholds for secretion of counterregulatory hormones and onset of physiological, symptomatic, and cognitive changes in response to hypoglycemia in the nondiabetic human. Reproduced from Frier and Fisher (8) in Hypoglycaemia in Clinical Diabetes. Reproduced with permission of John Wiley and Sons, Chichester, U.K. Nicola N. Zammitt, and Brian M. Frier Dia Care 2005;28: ©2005 by American Diabetes Association

Download ppt "Glycemic thresholds for secretion of counterregulatory hormones and onset of physiological, symptomatic, and cognitive changes in response to hypoglycemia."

Similar presentations

Diabetes Update Part 2 of 3 Division of Endocrinology

Diabetes Update Part 2 of 3 Division of Endocrinology
Management of Diabetes in the Older Person

Management of Diabetes in the Older Person
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Note: this is a content review activity; items are set to animate on any click. To enable more learner interactivity/control, use action buttons and.

Note: this is a content review activity; items are set to animate on any click. To enable more learner interactivity/control, use action buttons and.
Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Management of Diabetes in the Older Person

Management of Diabetes in the Older Person
Category 6 Category4 Category 5 Category 1 Category 2 Category 3

Category 6 Category4 Category 5 Category 1 Category 2 Category 3
תצפית.

תצפית.
Glycemic Control, Mealtime Glucose Excursions, and Diabetic Complications in Type 2 Diabetes Mellitus  P.J. Palumbo, MD  Mayo Clinic Proceedings  Volume.

Glycemic Control, Mealtime Glucose Excursions, and Diabetic Complications in Type 2 Diabetes Mellitus  P.J. Palumbo, MD  Mayo Clinic Proceedings  Volume.
Critiquing Cryos by Morie Gertz Blood Volume 111(11):

Critiquing Cryos by Morie Gertz Blood Volume 111(11):
Glucose homeostasis: roles of insulin and glucagon. 1A.

Glucose homeostasis: roles of insulin and glucagon. 1A.
PSYCHOLOGY IN ACTION Sixth Edition by Karen Huffman

PSYCHOLOGY IN ACTION Sixth Edition by Karen Huffman
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
Copyright © 2014 John Wiley & Sons, Inc. All rights reserved.

Copyright © 2014 John Wiley & Sons, Inc. All rights reserved.
Glycemic thresholds for subjective symptomatic awareness of hypoglycemia and for the onset of cognitive dysfunction in young and elderly nondiabetic males.

Glycemic thresholds for subjective symptomatic awareness of hypoglycemia and for the onset of cognitive dysfunction in young and elderly nondiabetic males.
Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
This CGM tracing of a 28-year-old patient with a 15-year history of type 1 diabetes demonstrates the occurrence of hypoglycemia unawareness lasting from.

This CGM tracing of a 28-year-old patient with a 15-year history of type 1 diabetes demonstrates the occurrence of hypoglycemia unawareness lasting from.

Similar presentations

Ads by Google